Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
Lexaria Bioscience Corp. (CSE;LXX) hit a major milestone this week with their patented DehydraTECHTM technology. An IC50 in vitro study was completed with COVID-19 SARS-CoV-2 antivirals Remdesivir and Ebastine and concluded that their formulation and processing methodology “did not negate the known efficacy of those compounds.”